Coexistent transthyretin amyloid cardiomyopathy and monoclonal gammopathy: Diagnostic challenges and prognostic implications

J Nucl Cardiol. 2022 Apr;29(2):519-527. doi: 10.1007/s12350-020-02281-3. Epub 2020 Jul 27.

Abstract

Establishing an accurate diagnosis of amyloid subtype in patients with coexistent cardiac amyloidosis and monoclonal gammopathy is crucial due to treatment and prognostic implications. Here, we discuss a case of coexistent diagnoses of transthyretin amyloid cardiomyopathy and smoldering multiple myeloma, highlighting the challenges associated with the possibility of several disease combinations and the limitations of diagnostic testing. In addition, the importance of clinical clues such as disease course and progression, patient preference, and multidisciplinary collaboration should not be discounted in the diagnostic and management approach of these patients.

Keywords: Amyloid heart disease; Cardiomyopathy; Diagnostic and prognostic application.

Publication types

  • Case Reports

MeSH terms

  • Amyloidosis* / complications
  • Amyloidosis* / diagnostic imaging
  • Cardiomyopathies* / complications
  • Cardiomyopathies* / diagnostic imaging
  • Humans
  • Monoclonal Gammopathy of Undetermined Significance* / complications
  • Paraproteinemias* / complications
  • Prealbumin
  • Prognosis

Substances

  • Prealbumin